ABCG2 Expression as a Potential Survival Predictor in Human Gliomas.

Gliomas are notably challenging to treat due to their invasive nature and resistance to conventional therapies. The ABCG2 protein has attracted attention for its role in multidrug resistance, complicating treatment effectiveness. This study scrutinized the relationship between ABCG2 expression and glioma grade and the role of ABCG2 in the process of glioma progression, aiming to evaluate ABCG2 expression as a predictive factor of tumor progression and patient survival. Conducted at Dubrava University Hospital, Zagreb, Croatia, the study analyzed 152 glioma specimens from 2013 to 2022, assessing ABCG2 expression alongside standard clinical markers. A significant association was found between patients' survival and the ABCG2 profile ( p = 0.003, r = 0.24), separately for patients who underwent chemotherapy ( p = 0.0004, r = 0.32) and radiotherapy ( p = 0.003, r = 0.29). Furthermore, the ABCG2 profile was significantly associated with disease progression ( p = 0.007, r = 0.23), tumor grade ( p = 0.0002, r = 0.31), and Ki67 expression ( p = 0.0004, r = 0.31). ABCG2-positive tumor cells only showed association with Ki67 expression ( p = 0.002, r = 0.28). The ABCG2 profile was found to affect the overall patient survival ( p = 0.02) and represent a moderate indicator of tumor progression ( p = 0.01), unlike the percentage of ABCG2-positive tumor cells. ABCG2 may serve as a marker of angiogenesis and vascular abnormalities within tumors, predicting glioma progression and treatment response. Targeting ABCG2 could enhance chemoradiotherapy efficacy and improve patient outcomes, which highlights its value in assessing tumor aggressiveness and designing treatment strategies.